AXIOS Stent & Delivery System Study
Completed · Not applicable
Conditions studied: Pancreatic Pseudocyst(s)
In brief
The Xlumena AXIOS Stent and Delivery System is an investigational device in the USA, and this study is being conducted under an Investigational Device Exemption (IDE) granted by the US Food and Drug Administration (FDA). The study design is prospective, multi-center, non-blinded, single-arm (nonrandomized) study. Up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States. Patients will be followed at (approximately) 30 days and/or 60 days depending upon pseudocyst resolution confirmation, at 1-week post-stent removal,and possibly at 3 and 6 month post-stent removal.
Key facts
- Study ID
- NCT01419769
- Run by
- Xlumena, Inc.
- People needed
- 30
- Starts
- 2011-08-01
- Expected to finish
- 2013-04-01
- Last updated by the study team
- 2015-09-21
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- (patients must meet all criteria)
- Age between 18 and 75 years old, male or female.
- Eligible for endoscopic intervention.
- Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage
- Symptomatic pancreatic pseudocyst having the following characteristics:
- Greater than or equal to 6 cm in size (based upon the maximum crosssectional area in the CT scan),
- Adherent to bowel wall, and
- ≥70% fluid content
- Patient understands the study requirements and the treatment procedures and provides written Informed Consent using a form that has been approved by the local Institutional Review Board or Ethics Committee before any study-specific tests or procedures are performed.
- Patient is willing to comply with all specified follow-up evaluations, including willingness to undergo a pre/post CT imaging study.
You may not qualify if…
- (patients meeting any of the below criteria will be excluded from study)
- <18 or >75 years of age
- Pancreatic pseudocysts having the following characteristics:
- Require nasocystic drainage,
- < 69% fluid content
- The fluid collection to be drained is an immature pseudocyst
- The fluid collection to be drained is a cystic neoplasm
- The fluid collection to be drained is a pseudoaneurysm
- The fluid collection to be drained is a duplication cyst
- The fluid collection to be drained is a non-inflammatory fluid collection
- There is more than one pseudocyst requiring drainage
- Abnormal coagulation:
- INR > 1.5 and not correctable
- presence of a bleeding disorder
- platelets < 50,000/mm3
- Altered anatomy that precludes the physician's ability to deliver the stent (decision on a case by case basis).
- Intervening gastric varices or vessels within a one centimeter radius of the needle (visible using endoscopy or endoscopic ultrasound)
- Any prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium), silicone or any other materials contacting the patient.
- Female of childbearing potential with a positive pregnancy test prior to the procedure or intends to become pregnant during the study.
- Currently participating in another investigational drug of device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
Where it is running
- California Pacific Medical Center (CPMC) — San Francisco, California, United States
- Unversity of Colorado Denver — Aurora, Colorado, United States
- Borland-Groover Clinic — Jacksonville, Florida, United States
- University of Chicago Medical Center (UCMC) — Chicago, Illinois, United States
- Cornell University — New York, New York, United States
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States
- Hospital Costa del Sol — Marbella, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.